News Releases

• July 24, 2012

  Great Lakes Pharmaceuticals, Inc. Announces Initiation of Clinical Study for Antimicrobial Lock Solution, B-Lock™.

  Beachwood, July 24, 2012 - Great Lakes Pharmaceuticals, Inc. announced today the initiation of the clinical study of the first Company product, the antimicrobial lock solution, B-Lock™. The prospective, randomized, active control clinical investigation is being conducted in 22 clinical sites in Hungary and Poland and will involve up to 400 patients on renal dialysis who require a central venous catheter for vascular access. The Company expects a wealth of clinical safety and efficacy data based on up to 45,000 catheter-days observations. If successful, the clinical data will be used for CE Mark approval in the European Union. More...PDF(56Kb)
• May 1, 2008

  Great Lakes Pharmaceuticals, Inc. Announces $2.4 Million Equity Financing

  Cleveland, OH, May 1, 2008 – Great Lakes Pharmaceuticals, Inc. announced today the completion of Series A $2.4 million equity financing led by Ohio investment funds including the North Coast Angel Fund JumpStart Inc., Everett Partners, Ltd, Ohio TechAngel Fund and Case Technology Ventures. The Company intends to use the funds to finalize the pre-clinical development and initiate pivotal clinical study of B-Lock™, an antimicrobial and heparin-free antithrombotic catheter lock solution. More...PDF(42Kb)
• January 30, 2008

  Great Lakes Pharmaceuticals, Inc. Announces the Signing of Exclusive License Agreements

  Cleveland, Ohio, (January 30, 2008) – Great Lakes Pharmaceuticals, Inc. announced today that it has entered into exclusive license agreements with The Board of Regents of The University of Texas System, acting on behalf of The University of Texas M. D. Anderson Cancer Center (“UTMDACC”), and Wake Forest University Health Sciences (“WFUHS"). More...PDF(43Kb)
• July 26, 2010

  Great Lakes Pharmaceuticals, Inc. Announces $3.1 Million Equity Financing Led by Charter Life Sciences

  CLEVELAND, OH--(Marketwire - July 26, 2010) - Great Lakes Pharmaceuticals, Inc. ("Great Lakes") announced today the completion of a $3.1 million Series B equity financing led by Charter Life Sciences. More...PDF(90Kb)
• June 29, 2009

  Great Lakes Pharmaceuticals, Inc. announces $2.6 million award from National Institutes of Health

  Beachwood, OH - (July 29, 2009) - Great Lakes Pharmaceuticals, Inc. announced that the Company has received a Notice of Award from the National Institutes of Health (NIH), National Heart, Lung, And Blood Institute (NHLBI) in support of the project "Development of B-Lock an antibiofilm catheter lock product". The $2.6 million grant will support efforts to move the Company's B-Lock™, an antimicrobial catheter lock solution, forward to human clinical trial testing for the prevention of infections related to central venous catheters. More... (12Kb)
• June 30, 2008

  Great Lakes Pharmaceuticals, Inc. Receives Fast Track SBIR Grant Award from NIH

  Beachwood, Ohio - Jun 30, 2008 (PRN): Great Lakes Pharmaceuticals, Inc. announced today that the company has received Phase One, $ 100,000 Fast Track Small Business Innovative Research (SBIR) grant from the National Institute of Health (NIH). More...PDF(71Kb)